- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Promising Role of Immunotherapy in Lung Cancer Treatment Emphasized at ELCC 2014
In the treatment of lung cancer, immunotherapy has come of age and is here to stay expert says at the 4th European Lung Cancer Conference.
A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.
Annals of Oncology
For decades, scientists and doctors thought immunotherapy — treatments that harness the immune system to fight a disease – was of marginal benefit in lung cancer, says ESMO spokesperson Jean-Charles Soria, Institute Gustave Roussy in Paris, France and Editor-in-Chief of .
However a new class of drugs known as “immunocheckpoint regulators” have shown huge potential, Soria says. New data on several of these drugs were presented at the conference.
Read the entire press release here:
http://bit.ly/1g2oeOF Source: European Society for Medical Oncology
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
